Veterinary PV

A pharmacovigilance system built for human medicines does not become a veterinary one just by changing the species field

About

Regulation (EU) 2019/6 shares its foundations with human GVP, but diverges on the details that actually matter: species-specific reactions, safety for non-target animals and the people handling the product, environmental impact, and for food-producing animals, Maximum Residue Limits.

A PV system adapted from human pharmacovigilance is structurally built to miss these points, and the gap shows up first in the PSMF-v and in EVVet reporting. We build the VGVP structure the regulation actually requires: PSMF-v documentation, EVVet reporting, and benefit-risk assessments defined around animal health from the start.

From the Trenches

Common Challenges we Solve

The Challenge

VGVP System Design

01

A PV system inherited from a human medicines programme is not built to capture species-specific reactions, safety signals in non-target animals, or human exposure from handling the product. These categories exist in Regulation 2019/6 but have no home in a standard human GVP process.

The Solution

A VGVP system designed around the categories the regulation actually tracks, with species-specific reaction coding and non-target animal and human exposure reporting built into intake from day one.

The Challenge

PSMF-v & EVVet Reporting

02

The Pharmacovigilance System Master File for Veterinary use and EudraVigilance Veterinary reporting follow their own structure and timelines, distinct from the human PSMF and EudraVigilance. A document built around the human version rarely holds up against what an inspector expects to see in a veterinary file.

The Solution

A PSMF-v built directly around VGVP requirements, with adverse event data mapped and tested against EVVet reporting standards before the first real submission.

The Challenge

Food Safety & Benefit-Risk for Food-Producing Animals

03

For food-producing species, a benefit-risk assessment has to account for Maximum Residue Limits, herd management practice, and the food safety chain, on top of the individual animal outcomes a human-style assessment is built around.

The Solution

Benefit-risk assessments that weigh MRLs, herd-level outcomes, and food safety alongside individual animal safety, structured to hold up under a VGVP-focused inspection.

The Challenge

04

The Solution

The Challenge

05

The Solution

The Challenge

06

The Solution

See our Other Areas of Expertise

Or contact us directly if there are any unsolved questions.

Veterinary PV

Building Your Commercial-Ready PV System:

While the principles of safety monitoring are universal, their application in specialized markets like animal health and cosmetics demands specific expertise.

The Founders

Independent pharmacovigilance leadership for small and mid-size pharma and biotech.

Agent image

Building PV systems for whatever situation put them under strain.

Stefan Brüning
Co-Founder and Consulting Practice Lead
LinkedIn Icon
Agent image

Responsible for leading human health and veterinary PV audits to help organisations build robust, inspection-ready PV systems.

Janine Gavin
Co-Founder and Audit Practice Lead
LinkedIn Icon

“Pharmacovigilance is a fundamental responsibility to patients, not just a regulatory checkbox. We make sure your systems reflect that.”

“Solid compliance is built before the auditor knocks. We help you get there — and stay there.”